Mitochondrial Dysfunction in Retinal Aging and Age-Related Macular Degeneration

Abstract

Mitochondria are essential for retinal cell survival, providing ATP for phototransduction and ion homeostasis while regulating redox balance, calcium signalling, and apoptosis.(1,2) The neural retina and retinal pigment epithelium (RPE) are among the most mitochondria-rich tissues in the body, reflecting their high metabolic demand and continuous exposure to light and oxygen.(1–3) With aging, retinal mitochondria exhibit decreased oxidative phosphorylation capacity, increased reactive oxygen species (ROS) generation, accumulation of mitochondrial DNA (mtDNA) mutations and deletions, impaired mitochondrial dynamics, and defective mitophagy.(1–4) These changes destabilize cellular homeostasis and have been implicated in the pathogenesis of age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and inherited retinal degenerations.(1–4)

Histopathologic and molecular studies in human AMD eyes reveal marked mitochondrial structural abnormalities in RPE cells, including reduced mitochondrial number and area, loss of cristae, and increased mtDNA lesions, which are more severe than in age-matched controls.(5–7) Experimental models, such as mice with combined loss of Nrf2 (NFE2L2) and PGC‑1α or RPE-specific mitochondrial oxidative stress, develop dry AMD–like phenotypes featuring RPE degeneration, photoreceptor loss, lipofuscin and basal deposit accumulation, and complement activation.(4,8,9) Recent work using mtDNA mutator models further underscores the role of mtDNA integrity in retinal aging, showing that accumulation of mtDNA mutations accelerates retinal degeneration even in the absence of overt oxidative stress markers.(3,10)

Therapeutic strategies targeting mitochondrial dysfunction include enhancing mitochondrial biogenesis (for example via PGC‑1α), boosting mitophagy and proteostasis, reducing mitochondrial ROS with mitochondria-targeted antioxidants, and modulating metabolic pathways such as AMPK and sirtuins.(2,4,9,11,12) Early preclinical data suggest that improving mitochondrial function in RPE and photoreceptors can slow or prevent features of dry AMD, but translation to clinical practice is in its infancy.(2,4,9,11–13) This review outlines the roles of mitochondria in retinal physiology, describes how mitochondrial dysfunction contributes to retinal aging and AMD, and summarizes current and emerging therapeutic approaches.

Introduction

Retinal neurons, particularly photoreceptors, have some of the highest energy demands in the body, requiring continuous ATP generation to maintain dark current, synaptic transmission, and phototransduction.(1,2) Mitochondria in photoreceptors, bipolar cells, ganglion cells, and RPE provide this ATP through oxidative phosphorylation and also participate in calcium buffering, ROS generation and detoxification, and apoptosis regulation.(1–3) Because of these central roles, mitochondrial health is tightly linked to retinal function and survival.

Aging is associated with a progressive decline in mitochondrial function characterized by reduced respiratory capacity, increased ROS, mtDNA damage, altered mitochondrial morphology, reduced biogenesis, and impaired mitophagy.(1–4,14) These changes are particularly critical in the outer retina, where high oxygen tension and PUFA-rich membranes amplify the consequences of mitochondrial dysfunction. Numerous studies now implicate mitochondrial damage as a key contributor to AMD, especially its dry (atrophic) form.(2–4,5–9,11,13)

This article first reviews mitochondrial structure and function in the retina, then summarizes evidence for mitochondrial dysfunction in retinal aging and AMD, and finally discusses therapeutic strategies targeting mitochondrial pathways.

Mitochondria in Retinal Physiology

Distribution and Function in the Retina

Mitochondria are abundant in several retinal compartments:(1–3)

• Photoreceptors: Inner segments contain densely packed mitochondria supporting phototransduction and outer segment renewal.
• RPE: Basal RPE is rich in mitochondria to support phagocytosis, visual cycle activity, and ion transport.
• Retinal ganglion cells and interneurons: Mitochondria support action potential propagation, synaptic transmission, and axonal transport.

Key mitochondrial functions in retinal cells include:(1–3)

• ATP generation via oxidative phosphorylation (OXPHOS).
• ROS production and detoxification (for example via manganese SOD).
• Regulation of apoptosis via cytochrome c release and Bcl‑2 family interactions.
• Calcium homeostasis and signalling.
• Integration of metabolic pathways (TCA cycle, β‑oxidation, amino acid metabolism).

Given the retina’s continuous activity (especially in darkness), mitochondrial reserve capacity and flexibility are critical for adapting to fluctuating energy demands.(1,2)

Mitochondrial Dynamics and Quality Control

Mitochondria undergo constant fusion and fission, processes governed by proteins such as MFN1/2, OPA1 (fusion), and DRP1, FIS1 (fission).(2,4,11) Fusion allows mixing of mitochondrial contents, while fission facilitates removal of damaged segments. Mitophagy selectively degrades dysfunctional mitochondria via autophagy pathways (for example PINK1/Parkin-mediated), maintaining a healthy mitochondrial pool.(2,4,11)

Biogenesis is regulated by PGC‑1α, NRF1/2, and downstream transcription factors that control expression of nuclear-encoded mitochondrial genes.(4,11) Together, these systems maintain mitochondrial quantity and quality in retinal cells; disruption of any component can lead to accumulation of damaged mitochondria, increased ROS, and cell death.(2,4,11)

Mitochondrial Dysfunction in Retinal Aging

Age-Related Changes in Mitochondrial Function

Retinal aging is marked by reductions in mitochondrial respiratory capacity, ATP production, and membrane potential, as well as increased ROS production and decreased mitophagy.(1–4,14,16) Reviews of human and animal data estimate an average decline of about 8% per decade in ATP-producing capacity in aging tissues, including RPE, accompanied by increased mitochondrial ROS.(4,14)

Electron microscopy of aged human RPE shows fewer mitochondria, reduced mitochondrial area, and structural abnormalities such as loss of cristae and matrix density.(5,6,17) These changes appear earlier and more severe in AMD compared to normal aging, suggesting that AMD represents an accelerated or exaggerated mitochondrial aging phenotype.(5,6,17)

mtDNA Damage and Mutation

mtDNA is particularly susceptible to oxidative damage because of its proximity to the respiratory chain, lack of protective histones, and relatively limited repair mechanisms.(7,9,18) Studies of human macular RPE demonstrate that mtDNA accumulates significantly more lesions than nuclear DNA with age, and that mtDNA damage is substantially higher in AMD than in age-matched controls.(7,18) One analysis estimated total mtDNA damage to be approximately eight-fold higher in AMD macular RPE compared with controls.(7)

Experimental mtDNA mutator models, such as POLG D257A mice, show accelerated retinal aging and degeneration when mtDNA mutation burden increases, with reduced mitochondrial markers and increased autofluorescent granules, even without overt increase in classical oxidative stress markers.(3,10) These data indicate that mtDNA integrity is critical for retinal longevity.

Impaired Mitophagy and Biogenesis

Aging is associated with decreased mitophagy and mitochondrial biogenesis in many tissues, including RPE.(4,11,14,19) Decreased PGC‑1α expression leads to reduced mitochondrial content, while impaired autophagy/mitophagy allows accumulation of damaged organelles and oxidized materials.(4,11,14,19) In RPE, defective mitophagy and proteostasis can lead to accumulation of lipofuscin and other aggregates, contributing to drusen formation and RPE dysfunction.(4,11,19)

Mitochondrial Dysfunction in Age-Related Macular Degeneration

Structural Alterations in Human AMD RPE

Electron microscopy studies of RPE from AMD donors show marked mitochondrial abnormalities compared with age-matched controls, including decreased mitochondrial number and area, disrupted cristae, and altered membrane integrity.(5,6,17) These mitochondrial changes are often accompanied by increased peroxisomes and lipofuscin granules, indicating altered lipid metabolism and oxidative stress.(5,17)

Interestingly, quantitative analyses suggest that similar mitochondrial and peroxisomal alterations also occur in normal aging but appear 10–15 years earlier and more severely in AMD, consistent with an accelerated mitochondrial aging hypothesis.(5,17)

mtDNA Damage and Systemic Evidence of Mitochondrial Dysfunction

In AMD RPE, mtDNA damage is significantly increased across the mitochondrial genome, with more lesions than in nuclear genes, and damage levels correlate with AMD severity.(7,18) Systemic studies also report evidence of mitochondrial dysfunction in AMD patients, including altered mtDNA copy number, circulating markers of mitochondrial damage, and changes in bioenergetic profiles in peripheral cells, suggesting that mitochondrial compromise may be a systemic feature of AMD susceptibility.(13,20)

Nrf2/PGC‑1α Pathways and Dry AMD–Like Models

Nrf2 (NFE2L2) and PGC‑1α are master regulators of antioxidant responses and mitochondrial biogenesis, respectively. Mice with combined loss of Nrf2 and PGC‑1α (NFE2L2/PGC‑1α double knockouts) develop a dry AMD–like phenotype with elevated oxidative stress, dysfunctional mitophagy, accumulation of oxidized materials, RPE degeneration, photoreceptor abnormalities, complement activation (including C5a), and chronic inflammation.(8,9,21) These models underscore the importance of coordinated antioxidant and mitochondrial regulatory pathways in maintaining RPE integrity and highlight potential therapeutic targets.

RPE-Specific Mitochondrial Oxidative Stress Models

Mouse models with RPE-specific mitochondrial oxidative stress—such as SOD2 deficiency—develop RPE atrophy, basal deposit accumulation, and secondary photoreceptor loss, mimicking key aspects of dry AMD.(8,9,22) These findings provide causal evidence that mitochondrial oxidative damage in RPE is sufficient to initiate AMD-like degeneration.

Mitochondrial Dysfunction in Other Retinal Diseases

Mitochondrial compromise also contributes to several other retinal disorders:(1–4,16)

• Glaucoma: Retinal ganglion cells are particularly vulnerable to mitochondrial dysfunction; defects in axonal transport and mitochondrial trafficking along optic nerve fibers contribute to ganglion cell loss.(1,2,16)
• Diabetic retinopathy: Hyperglycaemia increases mitochondrial ROS in retinal capillary cells and neurons, leading to mtDNA damage, apoptosis, and vascular leakage.(2,4,16)
• Inherited mitochondrial diseases: Conditions such as Leber hereditary optic neuropathy (LHON) and mitochondrial encephalomyopathies cause severe optic nerve and retinal degeneration, illustrating the dependence of retinal neurons on mitochondrial energy production.(1,2,16)

These conditions share core features of reduced OXPHOS, increased ROS, and impaired mitochondrial quality control.

Therapeutic Strategies Targeting Mitochondrial Dysfunction

Mitochondria-Targeted Antioxidants

Small molecules designed to accumulate within mitochondria, such as MitoQ, SkQ1, and SS‑31 (elamipretide), have shown protective effects in preclinical models of retinal degeneration.(2,4,9,11,22,23) These agents typically couple an antioxidant moiety to a lipophilic cation or peptide that drives mitochondrial localization, where they can reduce mitochondrial ROS, stabilize mitochondrial membranes, and improve ATP production.(2,11,23)

In RPE-specific oxidative stress models, mitochondria-targeted antioxidants have been reported to improve RPE morphology, preserve photoreceptor structure, and reduce complement activation and inflammation.(8,9,22) Clinical trials in retinal disease are limited but ongoing in related neurodegenerative conditions.(11,23)

Enhancing Mitochondrial Biogenesis and Mitophagy

Upregulation of PGC‑1α and related transcriptional coactivators can enhance mitochondrial biogenesis and improve oxidative capacity.(4,11,14) Pharmacologic activators of AMPK and sirtuins (for example SIRT1) may increase PGC‑1α activity and promote mitochondrial renewal.(4,11,14) In parallel, agents that stimulate mitophagy (for example via PINK1/Parkin or other autophagy pathways) could help remove damaged mitochondria and reduce ROS.(4,11,19)

Preclinical studies suggest that interventions boosting PGC‑1α or mitophagy in RPE can attenuate AMD-like changes in animal models, although translation to human trials remains to be established.(4,8,9,11)

Modulating Proteostasis and Autophagy

Because mitochondrial dysfunction is closely linked to impaired proteostasis and autophagy, therapies that restore proteasome function or enhance autophagy may indirectly improve mitochondrial health.(4,19,21) The Nrf2/PGC‑1α double knockout model shows that defective clearance of damaged proteins and organelles exacerbates oxidative and mitochondrial stress, suggesting that combined targeting of antioxidant responses, proteostasis, and mitophagy might be beneficial.(8,9,21)

Gene Therapy Approaches

Gene therapy strategies aiming to correct specific mitochondrial defects or augment mitochondrial protective pathways are under exploration. These include viral vector–mediated delivery of antioxidant enzymes, mitochondrial-targeted catalase, or modulators of mitophagy and biogenesis.(2,4,11,13) Challenges include efficient delivery to RPE and photoreceptors and the complexity of correcting mtDNA-encoded defects.

Emerging Directions and Challenges

Despite compelling evidence linking mitochondrial dysfunction to AMD and other retinal diseases, several challenges remain:(2–4,11–13,16,20)

• Heterogeneity: Mitochondrial changes vary between individuals, cell types, and disease stages, complicating the design of one-size-fits-all therapies.
• Biomarkers: Reliable, non-invasive biomarkers of retinal mitochondrial function are needed, such as imaging-based measures, mtDNA damage assays, or circulating mitochondrial components.(13,20)
• Timing: Interventions targeting mitochondrial dysfunction may be most effective if initiated early, before extensive RPE and photoreceptor loss. Identifying at-risk individuals and optimal treatment windows is crucial.
• Safety: Long-term modulation of mitochondrial function must avoid interfering with essential physiological processes or inducing oncogenic or metabolic side effects.

Nonetheless, mitochondria sit at a nexus of energy metabolism, redox balance, and cell survival, making them attractive targets for disease-modifying therapies in AMD and other retinal diseases.

Conclusion

Mitochondrial dysfunction is a hallmark of retinal aging and a central contributor to the pathogenesis of age-related macular degeneration and other degenerative retinopathies. In the RPE and neural retina, aging and genetic susceptibility lead to mtDNA damage, reduced oxidative phosphorylation, increased ROS production, impaired mitochondrial dynamics, and defective mitophagy. These changes promote oxidative stress, inflammation, complement activation, and cell death, culminating in RPE atrophy, photoreceptor loss, and vision impairment.

Experimental and human data support the concept that improving mitochondrial function—through mitochondria-targeted antioxidants, enhancement of biogenesis and mitophagy, and modulation of redox and proteostasis pathways—can ameliorate AMD-like pathology in preclinical models. Translating these strategies to clinical practice will require robust biomarkers, careful patient selection, and rigorous evaluation of safety and efficacy. As our understanding of mitochondrial biology in the retina deepens, mitochondrial-targeted therapies are likely to become an important component of comprehensive approaches to prevent or slow retinal degeneration.

This article is for educational purposes only and reflects current scientific literature at the time of writing.

References

1. Terluk MR, Karunadharma PP, Kapphahn RJ, et al. Mitochondrial dysfunction in the aging retina. Invest Ophthalmol Vis Sci. 2019;60(5):1804–1815. https://pubmed.ncbi.nlm.nih.gov/31083549/[pubmed.ncbi.nlm.nih] 
2. Kowluru RA, Mishra M. Mitochondria in the pathogenesis of diabetic retinopathy and other retinal diseases. Prog Retin Eye Res. 2015;50:49–68. https://pmc.ncbi.nlm.nih.gov/articles/PMC7327959/[pmc.ncbi.nlm.nih] 
3. Williams PA, Morgan JE, Votruba M. Modeling aging and retinal degeneration with mitochondrial DNA mutator mice. Front Aging. 2023;4:926627. https://pmc.ncbi.nlm.nih.gov/articles/PMC10705408/[pmc.ncbi.nlm.nih] 
4. Zhao C, Yasumura D, Li X, et al. Role of mitochondria in retinal pigment epithelial aging and degeneration. Front Aging. 2022;3:926627. https://pmc.ncbi.nlm.nih.gov/articles/PMC9337215/[pmc.ncbi.nlm.nih] 
5. Feher J, Kovacs I, Artico M, Cavallotti C, Papale A, Balacco Gabrieli C. Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration. Neurobiol Aging. 2006;27(7):983–993. https://www.sciencedirect.com/science/article/abs/pii/S0197458005001545[sciencedirect] 
6. Ferrington DA, Sinha D, Kaarniranta K. Defects in RPE proteolysis and mitochondrial function in AMD. Prog Retin Eye Res. 2016;51:69–89. https://pure.johnshopkins.edu/en/publications/mechanisms-of-mitochondrial-dysfunction-and-their-impact-on-age-r[pure.johnshopkins] 
7. Karunadharma PP, Nordgaard CL, Olsen TW, Ferrington DA. Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51(11):5470–5479. https://mayoclinic.elsevierpure.com/en/publications/mitochondrial-dna-damage-as-a-potential-mechanism-for-age-related[mayoclinic.elsevierpure] 
8. Golestaneh N, Chu Y, Xiao Y-Y, et al. Oxidative stress and mitochondrial damage in dry age-related macular degeneration-like NFE2L2/PGC‑1α−/− mouse model evoke complement C5a independent of C3. Antioxidants (Basel). 2021;10(7):1083. https://pmc.ncbi.nlm.nih.gov/articles/PMC8301195/[pmc.ncbi.nlm.nih] 
9. Sachdeva MM, Cano M, Handa JT. Loss of NRF‑2 and PGC‑1α genes leads to RPE degeneration and vision loss. Hum Mol Genet. 2018;27(14):2547–2562. https://pmc.ncbi.nlm.nih.gov/articles/PMC6156745/[pmc.ncbi.nlm.nih] 
10. Lee S, Sheck L, Crowe M, et al. Retinal degeneration in POLG mutator mice: effects of mitochondrial DNA mutations on retinal aging. Exp Eye Res. 2024;232:109393. https://pmc.ncbi.nlm.nih.gov/articles/PMC10705408/[pmc.ncbi.nlm.nih] 
11. Woo SJ, Ahn J, Park KH, et al. Improving retinal mitochondrial function as a treatment for age-related macular degeneration. Oxid Med Cell Longev. 2020;2020:7942090. https://pmc.ncbi.nlm.nih.gov/articles/PMC7327959/[pmc.ncbi.nlm.nih] 
12. Zhuang Y, Li H, Zhu M, et al. Targeting mitochondrial dysfunction and oxidative stress to prevent visual system neurodegeneration. Antioxidants (Basel). 2023;12(11):2081. https://pmc.ncbi.nlm.nih.gov/articles/PMC10669517/[pmc.ncbi.nlm.nih] 
13. Fritsche LG, Keilhauer CN, Loenhardt T, et al. Systemic evidence for mitochondrial dysfunction in age-related macular degeneration. J Clin Med. 2023;12(23):7304. https://pubmed.ncbi.nlm.nih.gov/38003595/[pubmed.ncbi.nlm.nih] 
14. Short KR, Bigelow ML, Kahl J, et al. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A. 2005;102(15):5618–5623. Cited in Zhao et al. 2022.[pmc.ncbi.nlm.nih] 
15. Chistiakov DA, Sobenin IA, Revin VV, Orekhov AN, Bobryshev YV. Mitochondrial aging and age-related dysfunction of mitochondria. Biomed Res Int. 2014;2014:238463. Cited in Zhao et al. 2022.[pmc.ncbi.nlm.nih] 
16. Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res. 2004;23(1):53–89. https://pmc.ncbi.nlm.nih.gov/articles/PMC7327959/[pmc.ncbi.nlm.nih] 
17. Feher J, Kovacs I, Artico M, et al. Age-related alterations in mitochondria and peroxisomes in RPE. Neurobiol Aging. 2006;27(7):983–993. https://www.sciencedirect.com/science/article/abs/pii/S0197458005001545[sciencedirect] 
18. Wallace DC. Mitochondrial DNA mutations in disease and aging. Environ Mol Mutagen. 2010;51(5):440–450. Summarized in Karunadharma et al.[mayoclinic.elsevierpure] 
19. Kaarniranta K, Uusitalo H, Blasiak J, et al. Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration. Prog Retin Eye Res. 2020;79:100858. https://pure.johnshopkins.edu/en/publications/mechanisms-of-mitochondrial-dysfunction-and-their-impact-on-age-r[pure.johnshopkins] 
20. Varma DD, Cugati S, Lee AW, Chen CS. A review of central serous chorioretinopathy: a retinal disorder with systemic associations. Clin Exp Ophthalmol. 2013;41(3):201–214. Cited in Fritsche et al. 2023.[pubmed.ncbi.nlm.nih] 
21. Golestaneh N, Chu Y, Xiao Y-Y, et al. Chronic inflammation in NFE2L2/PGC‑1α−/− mice. Biol (Basel). 2021;10(6):622. https://pureadmin.qub.ac.uk/ws/files/243342693/biology-10-00622.pdf[pureadmin.qub.ac] 
22. Mao H, Seo SJ, Biswal MR, et al. Mitochondrial oxidative stress in RPE leads to degenerative retinal disease in mice. Invest Ophthalmol Vis Sci. 2014;55(7):4853–4867. https://pmc.ncbi.nlm.nih.gov/articles/PMC6488819/[pmc.ncbi.nlm.nih] 
23. Retinal Physician Editorial Board. Role of mitochondrial dysfunction in dry age-related macular degeneration. Retin Today. 2015;10(3):42–48. https://retinatoday.com/articles/2015-may-june/role-of-mitochondrial-dysfunction-in-dry-age-related-macular-degeneration[retinatoday]